Tirzepatide has emerged as a groundbreaking medication for type 2 diabetes, offering promising effects. However, the expense of this innovative drug and its access have become key issues for patients and healthcare practitioners. While tirzepatide has been authorized by regulatory agencies, its expensive nature presents a significant challenge to